Crossmark

Systematic review of the efficacy and safety of lenvatinib vs. sorafenib as first-line treatments for hepatocellular carcinoma

Crossref DOI link: https://doi.org/10.1016/j.clinsp.2026.100869

Published Print: 2026-01

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Bo, Wentao https://orcid.org/0009-0006-4085-6956
Wang, Zhenguo https://orcid.org/0009-0004-7721-512X
Dong, Xiuhua https://orcid.org/0009-0006-8554-8869
Zou, Jing https://orcid.org/0009-0001-2056-8651
License Information

Text and Data Mining valid from 2026-01-01

Text and Data Mining valid from 2026-01-01

Version of Record valid from 2026-02-08
More Information

This article is maintained by: Elsevier

Article Title: Systematic review of the efficacy and safety of lenvatinib vs. sorafenib as first-line treatments for hepatocellular carcinoma

Journal Title: Clinics

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.clinsp.2026.100869

Content Type: article

Copyright: © 2026 HCFMUSP. Published by Elsevier España, S.L.U.